Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout

Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, enhancing its focus on rare diseases. The deal is expected to expand Biogen's therapeutic pipeline and strengthen its position in the biotech sector.

• Biogen acquires Apellis for $5.6 billion
• Enhances rare disease pipeline